p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases

Tumori

Volumn 90, Issue 1, 2004, Pages 120-127

  Batinac, Tanja ^a   Zamolo, Gordana ^b   Jonjić, Nives ^b   Gruber, Franjo ^a   Petrovečki, Mladen ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Immunohistochemistry; Ki 67 antigen; p53 protein; Psoriasis; Skin neoplasms

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BASAL CELL CARCINOMA; BIOACCUMULATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSPLASIA; EPIDERMIS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; PROTEIN EXPRESSION; PSORIASIS; SKIN DISEASE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 2142708089     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000124     Document Type: Article

References (39)

1. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor. Nature, 351: 453-456, 1991.
2. Heenen M: Cell cycle: regulation and abnormalities in epidermal tumors. Ann Dermatol Venereol, 124: 452-456, 1997.
3. Helender SD, Peters MS, Pittelkow MR: Expression of p53 protein in benign and malignant epidermal pathological conditions. J Am Acad Dermatol, 29: 741-748, 1993.
4. Lane DP: P53, guardian of the genome. Nature, 358: 15-16, 1992.
5. Depert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K: Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene, 5: 1701-1706, 1990.
6. Milner J: The role of p53 in the normal control of cell proliferation. Curr Opin Cell Biol, 3: 282-286, 1991.
7. Golusinski W, Olofsson J, Szmeja Z, Szyfter K, Szyfter W, Biczysko W, Hemminki K: Alteration of p53 gene structure and function in laryngeal squamous cell cancer. Eur Arch Otorhinolaryngol, 254 (Suppl 1): S 133-137, 1997.
8. D'Errico M, Dogliotti E: The role of p53 mutations in skin cancer. Chron Derm, 6: 27-35, 1996.
9. Liang SB, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Chen BK, Sonobe H: Sun-exposure- and aging-dependent p53 protein accumulation results in growth advantage for tumor cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch, 434: 193-199, 1999.
10. Furihata M, Sonobe H, Ohtsuki Y: The aberrant p53 protein (review). Int J Oncol, 6: 1209-1226, 1995.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 in the cellular response to DNA damage. Cancer Res, 51: 6304-6311, 1991.
12. Nelson WG, Kastan M: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol, 14: 1815-1823, 1994.
13. Hall PA, McKee PH, Menage HD, Dover R, Lane DP: High level of p53 protein in UV-irradiated normal skin. Oncogene, 8: 203-207, 1993.
14. Hermeking H, Eick D: Mediation of c-myc induced apoptosis by p53. Science, 265: 2091-2093, 1994.
15. Dittmer D, Pati S, Zambetti G, Chu S, Tereski AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nature Genet, 4: 42-46, 1993.
16. Milner J, Medcalf EA: Cotranslation of activated mutant p53 wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65: 765-774, 1991.
17. Soini Y, Kamel D, Paakko P, Lehto PV, Oikarinen A, Vahakangas K: Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol, 131: 514-520, 1994.
18. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, Vahakangas K: Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venerol, 79: 195-199, 1999.
19. Smolle J, Sojer H-P, Kerl H: Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody: a quantitative immunohistochemical study. Am J Dermatopathol, 1989; 11: 301-307, 1989.
20. Chung JH, Kwon OS, Eun HC, Youn JI, Song YW, Kim JG, Cho KH: Apoptosis in the pathogenesis of cutaneous lupus erythematosus. Am J Dermatopathol, 20: 233-241, 1998.
21. Brown DC, Gatter KC: Ki-67 protein: the immaculate deception? Histopathology, 40: 2-11, 2002.
22. Shimizu T, Oga A, Murakami T, Muto M: Overexpression of p53 protein associated with proliferative activity and histological degree of malignancy in solar keratosis. Dermatology, 199: 113-118, 1999.
23. Shimitzu T, Muto M, Murakami T, Furumoto H, Mogami S, Asagami C: Overexpression of p53 protein associated with proliferative activity as evaluated by Ki-67 immunostaining in well-differentiated squamous cell carcinoma of the skin. Dermatology, 195: 224-227, 1997.
24. Onodera H, Nakamura S, Sugui T: Cell proliferation and p53 protein expression in cutaneous epithelial neoplasms. Am J Dermatopathol, 18: 580-588, 1996.
25. Ro YS, Cooper PN, Lee JA, Quinn AG, Harrison D, Lane D, Horne CH, Ress JL, Angus B: P53 protein expression in benign and malignant skin tumors. Br J Dermatol, 128: 237-241, 1993.
26. Bishop JM: Molecular themes in oncogenesis. Cell, 64: 235-248, 1991.
27. Marshall CJ: Tumor suppressor genes. Cell, 64: 313-326, 1991.
28. Tadini G, Cerri A, Crosti L, Cattoretti G, Berti E: p53 and oncogene expression in psoriasis. Acta Derm Venerol, 146: 33-35, 1989.
29. Moles JP, Theillet C, Basset-Seguin N, Guilhou JJ: Mutation of the tumor suppressor gene TP53 is not detected in psoriatic skin. J Invest Dermatol, 101: 100-102, 1993.
30. Kubo Y, Urano Y, Yoshimoto K, Iwahana H, Fukuhara K, Arase S, Itakura M: P53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol, 102: 440-444, 1994.
31. Mercer WE, Shields MT, Lin D: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA, 88: 1958-1962, 1991.
32. Kerschmann RL, McCalmont TH, LeBoit PE: P53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol, 130: 181-186, 1994.
33. Perez MI, Robins P, Biria S, Roco J, Siegel E, Pellicer A: P53 oncoprotein expression and gene mutations in some keratoacanthomas. Arch Dermatol, 133: 189-193, 1997.
34. Baum HP, Meurer I, Unteregger G: Ki-67 antigen expression and growth pattern of basal cell carcinomas. Arch Dermatol Res, 285: 291-295, 1993.
35. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE: Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA, 93: 14025-14029, 1996.
36. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN: P53 mutations in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol, 109: 238-243, 1997.
37. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familiar syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250: 1233-1238, 1990.
38. Ouhtit A, Ueda M, Nakazawa H, Ichihashi M, Dumaz N, Sarasin A, Yamasaki H: Quantitative detection of ultraviolet-specific p53 mutations in normal skin from Japanese patients. Cancer Epidemiol Biomarkers Prev, 6: 433-438, 1997.
39. D'Errico M, Calcagnile AS, Corona R, Fucci M, Annessi G, Baliva G, Tosti ME, Pasquinni P, Dogliotti E: p53 mutations and chromosome instability in basal cell carcinomas developed at an early or late stage. Cancer Res, 57: 747-752, 1997.